• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14C filed by PPD, Inc.

    5/26/21 4:55:35 PM ET
    $PPD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PPD alert in real time by email
    DEFR14C 1 d238109ddefr14c.htm DEFR14C DEFR14C

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14C INFORMATION

    Information Statement Pursuant to Section 14(c) of the

    Securities Exchange Act of 1934

    Amendment No. 1

    Check the appropriate box:

     

    ☐   Preliminary information statement
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
    ☒   Definitive information statement

    PPD, Inc.

     

     

    (Name of Registrant as Specified in Its Charter)

    Payment of Filing Fee (Check the appropriate box):

    ☐   No fee required.
    ☐   Fee computed below per Exchange Act Rules 14c-5(g) and 0-11
      (1)  

    Title of each class of securities to which transaction applies:

     

      (2)  

    Aggregate number of securities to which transaction applies:

     

      (3)  

    Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

     

      (4)  

    Proposed maximum aggregate value of transaction:

     

      (5)  

    Total fee paid:

     

    ☒   Fee paid previously with preliminary materials.
    ☐   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
      1)  

    Amount Previously Paid:

     

         

      2)  

    Form, Schedule or Registration Statement No.:

     

         

      3)  

    Filing Party:

     

         

      4)  

    Date Filed:

     

         

     

     


    PPD, Inc.

    929 North Front Street

    Wilmington, North Carolina 28401

    The following information is being provided to amend PPD Inc.’s (the “Company”) definitive information statement filed with the Securities and Exchange Commission on May 25, 2021 (the “information statement”). Text that is bold and struck through in the disclosures below shows text being removed from those disclosures and text that is bold and underlined below shows text being added to those disclosures. Terms used but not otherwise defined herein have the meanings given to them in the information statement, and all references to captions and page numbers refer to captions and page numbers in the information statement, respectively, unless otherwise provided.

    Except as otherwise set forth below, the information set forth in the information statement remains unchanged and is incorporated by reference as relevant to the items in this Amendment No. 1 to the information statement.

    THE INFORMATION STATEMENT CONTAINS IMPORTANT ADDITIONAL INFORMATION AND THIS AMENDMENT SHOULD BE READ IN CONJUNCTION WITH THE INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

     

    1.

    The second sentence of the fourth paragraph on the cover page of the information statement is amended and restated in its entirety as follows:

    To exercise your appraisal rights, you must submit a written demand for an appraisal to the Company no later than twenty (20) days after the mailing of this information statement, which mailing date is May 2526, 2021, and comply precisely with other procedures set forth in Section 262 of the DGCL, which are summarized in the accompanying information statement.

     

    2.

    The last sentence on the cover page of the information statement is amended and restated in its entirety as follows:

    This information statement is dated May 25, 2021 and is first being mailed to stockholders on or about May 2526, 2021.

     

    3.

    The sixth sentence of the first paragraph in the section entitled “Summary” on page 1 of the information statement is amended and restated in its entirety as follows:

    This information statement is dated May 25, 2021 and is first being mailed to our stockholders on or about May 2526, 2021.

     

    4.

    The third sentence of the first paragraph in the section entitled “Summary—Appraisal Rights (page 64 and Annex C)” on page 7 of the information statement is amended and restated in its entirety as follows:

    In order to exercise your appraisal rights, you must submit a written demand for an appraisal of your shares no later than 20 days after the date of mailing of this notice and the accompanying information statement, which mailing date is May 2526, 2021, and precisely comply with other procedures set forth under Section 262 of the DGCL.

     

    5.

    The first sentence of the sixth paragraph in the section entitled “Appraisal Rights” on page 64 of the information statement is amended and restated in its entirety as follows:

    Holders of shares of Company Common Stock who desire to exercise their appraisal rights must submit to the Company a written demand for appraisal of their shares of Company Common Stock no later than 20 days after the date of mailing of this information statement (which includes the notice of written consent and appraisal rights), which mailing date is May 2526, 2021.

    WHERE YOU CAN FIND MORE INFORMATION

    We file annual, quarterly and current reports, proxy statements, and other documents with the SEC. These reports contain additional information about the Company. Stockholders may read and copy any reports, statements or other information filed by the Company at the SEC’s Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of this information by mail from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates. Please call the SEC at (800) SEC-0330 for further information on the operation of the Public Reference Room. The Company’s SEC filings are made electronically available to the public at the SEC’s website located at www.sec.gov. Stockholders can also obtain free copies of our SEC filings through the “Investor Relations” section of the Company’s website at https://investors.ppd.com/investor-relations. Our website address is being provided as an inactive textual reference only. The information provided on, or accessible through, our website, other than the copies of the documents listed or referenced in the information statement that have been or will be filed with the SEC, is not part of the information statement, as amended, and therefore is not incorporated herein by reference.

    The Company undertakes to provide without charge to each person to whom a copy of the information statement, as amended, has been delivered, upon written or oral request, by first class mail or other equally prompt means within one business day of


    receipt of such request, a copy of any or all of the documents incorporated by reference in the information statement, as amended, other than the exhibits to these documents, unless the exhibits are specifically incorporated by reference into the information that the information statement, as amended, incorporates. You may request a copy of these filings by telephone at (910) 251-0081 or by writing to us at:

    Investor Relations

    929 North Front Street

    Wilmington, NC 28401

    e-mail: [email protected]

    Thermo Fisher and Merger Sub have supplied, and the Company has not independently verified, the information in the information statement, as amended, relating to Thermo Fisher and Merger Sub.

    Stockholders should not rely on information that purports to be made by or on behalf of the Company other than that contained in or incorporated by reference in the information statement, as amended. The Company has not authorized anyone to provide information on behalf of the Company that is different from that contained in the information statement, as amended. This Amendment No. 1 to the information statement is dated May 26, 2021. No assumption should be made that the information contained in the information statement, as amended, is accurate as of any date other than that date, and the mailing of the information statement, as amended, will not create any implication to the contrary.

     

     

    2

     

    Get the next $PPD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPD

    DatePrice TargetRatingAnalyst
    8/5/2021$47.50Neutral
    Credit Suisse
    More analyst ratings

    $PPD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

      WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (NASDAQ:PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapi

      12/8/21 8:45:00 AM ET
      $PPD
      $TMO
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Industrial Machinery/Components
      Industrials
    • PPD Named to 'Best Workplaces in Greater China' for Second Consecutive Year

      PPD, Inc. (NASDAQ:PPD) was named one of the "Best Workplaces in Greater China™ 2021" by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. "We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year," said D

      12/7/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Financials

    Live finance-specific insights

    See more
    • PPD Announces Third Quarter 2021 Earnings Conference Call

      PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5

      10/18/21 4:05:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) f

      11/30/20 6:59:00 AM ET
      $MRNA
      $PPD
      $MCK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Other Pharmaceuticals

    $PPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/9/21 5:14:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 5:05:14 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:53:26 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on PPD with a new price target

      Credit Suisse resumed coverage of PPD with a rating of Neutral and set a new price target of $47.50

      8/5/21 6:25:35 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by JP Morgan with a new price target

      JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00

      4/28/21 10:25:55 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Jefferies

      Jefferies downgraded PPD from Buy to Hold

      4/20/21 8:11:33 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    SEC Filings

    See more
    • SEC Form 15-12B filed by PPD, Inc.

      15-12B - PPD, Inc. (0001793294) (Filer)

      12/20/21 5:20:22 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PPD, Inc.

      S-8 POS - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:16:02 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:12:04 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PPD, Inc.

      SC 13G - PPD, Inc. (0001793294) (Subject)

      12/9/21 5:06:56 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 4:19:09 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 6:11:58 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Leadership Updates

    Live Leadership Updates

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care